Up-front infliximab dose intensification for secondary loss of response in inflammatory bowel disease: Similar efficacy to dose-interval shortening with the added advantage of early clinical and pharmacokinetic predictors of durable response-MedSci.cn

Up-front infliximab dose intensification for secondary loss of response in inflammatory bowel disease: Similar efficacy to dose-interval shortening with the added advantage of early clinical and pharmacokinetic predictors of durable response

Srinivasan, A; De Cruz, P; Sam, M; Toong, C; Van Langenberg, D

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022; 37 (): 137

科室
- - 订阅+
  - 更多科室
工具
服务